Cargando…
Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
INTRODUCTION: The lack of feasible therapies and comorbidities aggravate the COVID-19 case–fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162097/ https://www.ncbi.nlm.nih.gov/pubmed/37153358 http://dx.doi.org/10.2147/JMDH.S403700 |
_version_ | 1785037629688905728 |
---|---|
author | Said, Kamaleldin B Alsolami, Ahmed Alreshidi, Fayez Saud Fathuddin, Anas Alshammari, Fawwaz Alrashid, Fauwaz Aljadani, Ahmed Aboras, Rana Alreshidi, Fatmah Alghozwi, Mohammed H Alshammari, Suliman F Alharbi, Nawaf F |
author_facet | Said, Kamaleldin B Alsolami, Ahmed Alreshidi, Fayez Saud Fathuddin, Anas Alshammari, Fawwaz Alrashid, Fauwaz Aljadani, Ahmed Aboras, Rana Alreshidi, Fatmah Alghozwi, Mohammed H Alshammari, Suliman F Alharbi, Nawaf F |
author_sort | Said, Kamaleldin B |
collection | PubMed |
description | INTRODUCTION: The lack of feasible therapies and comorbidities aggravate the COVID-19 case–fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing hydroxychloroquine (Hcq) and antivirals are needed. PURPOSE: To examine associations of COVID-19 CFR in comorbid patient groups each with single comorbidities and after treatment with Hcq, favipiravir, and dexamethasone (Dex), either alone or in combination versus standard care. METHODS: Using statistical analysis, we descriptively determined these associations among 750 COVID-19 patient groups during the last quarter of 2021. RESULTS: A diabetes comorbidity (40%, n=299) showed twice the fatality (CFR 14%) of the others (CFR 7%; P=0.001). Hypertension (Htn) was the second-commonest comorbidity (29.5%, n=221), with similar CFR to diabetes (15% and 7% for Htn and non-Htn, respectively), but with higher significance (P=0.0006167). Although only 4% (n=30) heart failure (HF) was reported, the CFR (40%) was much higher than in those without it (8%). A similar rate (4%) for chronic kidney disease was reported, with CFRs of 33% and 9% among those with and without it, respectively (P=0.00048). Ischemic heart disease was 11% (n=74), followed by chronic liver disease (0.4%) and history of smoking (1%); however, these were not significant due to the sample sizes. Treatment indicated standard care and Hcq alone or in combination were superior (CFR of 4% and 0.5%, respectively) compared to favipiravir (25%) or Dex (38.5%) independently or in combination (35.4%). Furthermore, Hcq performed well (CFR 9%) when combined with Dex (9%; P=4.28–(26)). CONCLUSION: The dominance of diabetes and other comorbidities with significant association with CFR implied existence of a common virulence mechanism. The superiority of low-dose Hcq and standard care over antivirals warrants further studies. |
format | Online Article Text |
id | pubmed-10162097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101620972023-05-06 Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals Said, Kamaleldin B Alsolami, Ahmed Alreshidi, Fayez Saud Fathuddin, Anas Alshammari, Fawwaz Alrashid, Fauwaz Aljadani, Ahmed Aboras, Rana Alreshidi, Fatmah Alghozwi, Mohammed H Alshammari, Suliman F Alharbi, Nawaf F J Multidiscip Healthc Original Research INTRODUCTION: The lack of feasible therapies and comorbidities aggravate the COVID-19 case–fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing hydroxychloroquine (Hcq) and antivirals are needed. PURPOSE: To examine associations of COVID-19 CFR in comorbid patient groups each with single comorbidities and after treatment with Hcq, favipiravir, and dexamethasone (Dex), either alone or in combination versus standard care. METHODS: Using statistical analysis, we descriptively determined these associations among 750 COVID-19 patient groups during the last quarter of 2021. RESULTS: A diabetes comorbidity (40%, n=299) showed twice the fatality (CFR 14%) of the others (CFR 7%; P=0.001). Hypertension (Htn) was the second-commonest comorbidity (29.5%, n=221), with similar CFR to diabetes (15% and 7% for Htn and non-Htn, respectively), but with higher significance (P=0.0006167). Although only 4% (n=30) heart failure (HF) was reported, the CFR (40%) was much higher than in those without it (8%). A similar rate (4%) for chronic kidney disease was reported, with CFRs of 33% and 9% among those with and without it, respectively (P=0.00048). Ischemic heart disease was 11% (n=74), followed by chronic liver disease (0.4%) and history of smoking (1%); however, these were not significant due to the sample sizes. Treatment indicated standard care and Hcq alone or in combination were superior (CFR of 4% and 0.5%, respectively) compared to favipiravir (25%) or Dex (38.5%) independently or in combination (35.4%). Furthermore, Hcq performed well (CFR 9%) when combined with Dex (9%; P=4.28–(26)). CONCLUSION: The dominance of diabetes and other comorbidities with significant association with CFR implied existence of a common virulence mechanism. The superiority of low-dose Hcq and standard care over antivirals warrants further studies. Dove 2023-05-01 /pmc/articles/PMC10162097/ /pubmed/37153358 http://dx.doi.org/10.2147/JMDH.S403700 Text en © 2023 Said et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Said, Kamaleldin B Alsolami, Ahmed Alreshidi, Fayez Saud Fathuddin, Anas Alshammari, Fawwaz Alrashid, Fauwaz Aljadani, Ahmed Aboras, Rana Alreshidi, Fatmah Alghozwi, Mohammed H Alshammari, Suliman F Alharbi, Nawaf F Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals |
title | Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals |
title_full | Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals |
title_fullStr | Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals |
title_full_unstemmed | Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals |
title_short | Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals |
title_sort | profiles of independent-comorbidity groups in senior covid-19 patients reveal low fatality associated with standard care and low-dose hydroxychloroquine over antivirals |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162097/ https://www.ncbi.nlm.nih.gov/pubmed/37153358 http://dx.doi.org/10.2147/JMDH.S403700 |
work_keys_str_mv | AT saidkamaleldinb profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alsolamiahmed profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alreshidifayezsaud profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT fathuddinanas profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alshammarifawwaz profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alrashidfauwaz profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT aljadaniahmed profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT aborasrana profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alreshidifatmah profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alghozwimohammedh profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alshammarisulimanf profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT alharbinawaff profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals AT profilesofindependentcomorbiditygroupsinseniorcovid19patientsreveallowfatalityassociatedwithstandardcareandlowdosehydroxychloroquineoverantivirals |